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Circadian oscillation and cell cycle progression are the two most essential rhythmic events present in almost all organisms.
Circadian rhythms keep track of time and provide temporal regulation with a period of about 24h. The cell cycle is optimized for
growth and division, but not for time keeping. Circadian gated cell divisions are observed in nearly all organisms. However, the
implications of this coupling to the physiology of mammals are unknown. A mutation (S662G) in the clock protein PERIOD2
(PER2) is responsible for familial advanced sleep phase syndrome in which sleep onset occurs in the early evening and
wakefulness occurs in the early morning. Here, we provide evidence that the PER2
S662 mutation leads to enhanced resistance to
X-ray-induced apoptosis and increased E1A- and RAS-mediated oncogenic transformation. Accordingly, the PER2
S662 mutation
affects tumorigenesis in cancer-sensitized p53
R172H/þ mice. Finally, analyzing the clock-controlled cell cycle genes p21, c-Myc,
Cyclin D1 and p27, we found that the relative phases between p21 and Cyclin D expression proﬁles have been changed
signiﬁcantly in these Per2 allele mutant mouse embryonic ﬁbroblasts. This key role of the Per2-mediated phase alteration of p21
provides what we believe to be a novel mechanism in understanding cell cycle progression, its plasticity and its resistance to
interference.
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The circadian clock is essential for the maintenance of
physiological homeostasis, as well as the coordination of
responses to external signals. In mammals, the circadian clock
is composed of interlocking positive and negative feedback
loops. In the primary feedback loop, three basic helix–loop–helix
(bHLH)/PAS domain-containing transcription factors, Clock,
Npas2 and Bmal1, activate the transcription of two period genes
(Per1 and Per2) and two cryptochrome (Cry) genes (Cry1 and
Cry2) by binding to the E-box cis elements in the promoters of
these genes. Subsequently, the PER/CRY complex inhibits the
transcription of its own genes by blocking BMAL1/CLOCK
activity. The second feedback loop is mediated by the orphan
nuclear receptors RORa and Rev-erba. Transcription of RORa
and Rev-erba is activated during the day by the CLOCK/BMAL1
complex, after which they exert positive and negative transcrip-
tional effects on the Bmal1 gene through Rev-erba/RORa
responsive elements (ROREs) in the Bmal1 promoter.
1–3 The
circadiansystemmaybetightlyconnectedtomanyphysiological
processes through clock-controlled nuclear receptor genes
(e.g., PPARa and PPARg) and cell cycle genes (e.g., c-Myc,
cyclin D, Wee1 and p21).
5–8 The links between the circadian
clock and a variety of physiological processes are just beginning
to be unveiled; however, the underlying mechanisms remain
unclear.
A major consequence of a modern lifestyle is the disruption
of circadian rhythms. Importantly, epidemiological studies
have shown that a disruption in circadian rhythms increases
an individual’s risk of developing colon, breast, prostate,
ovarian, lung and liver cancer.
9,10 The International Agency
for Research on Cancer has elevated the carcinogenicity of
circadian disruption from Group 2B to Group 2A.
11 Further-
more, several studies using mouse models have established
convincinglinksbetweenmutationsincertainclockgenesand
tumorigenesis. Targeted disruption of PERIOD2 (Per2) leads
to tumor susceptibility in the presence of g radiation.
6 Per1
also functions as a tumor suppressor by regulating cell cycle
genes and by interacting with key checkpoint proteins that are
activated by DNA damage.
8 Given the strong links between
circadian rhythms and the diverse physiological processes in
these animal models, it is important to address whether
human circadian variations inﬂuence cancer susceptibility.
Advanced sleep phase syndrome (ASPS) is a circadian
rhythm variant in which sleep onset occurs in the early
evening (i.e., 1800–2000hours) and, as a consequence,
wakefulness occurs in the early morning (i.e., 0100–
0300h).
12–14 The discovery that the PER2
S662G mutation
causes familial ASPS (FASPS) was the ﬁrst direct evidence
that PER2 has an essential role in the human circadian
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13,15 Furthermore, given that this speciﬁc amino acid of
the PER2 protein may represent an appealing therapeutic
target,weinvestigatedwhethertheS662siteisalsocrucialfor
its function as a tumor suppressor. Moreover, PER2
S662G and
PER2
S662Dtransgenicmiceareuniquebecausesingleamino-
acid changes at this site can either shorten or lengthen the
circadian period in a mutation-dependent manner, thus
providing a unique model to understand how circadian period
length affects cell cycle progression and tumorigenesis.
In the present study, we focused on characterizing the link
between PER2
S662 mutations and tumorigenesis both in vitro
and in vivo. We found that mutation of PER2
S662 affects
tumorigenesis in p53
R172H/þ mice, which have a cancer-
sensitized genetic background caused by a p53 knock-in
mutation
2H.
16 We subsequently found that PER2 acts as a
phaseregulator,directlyorindirectly,toaffecttheadvancedor
delayedcellcyclegeneexpressionproﬁles,butnotamplitude.
Theseﬁndingsraisethepossibilitythatalterationofp21phase
by Per2 allele mutant may interfere with cell phase locking to
promote cell cycle progression.
Results
S662 is a key amino acid in PER2 that modulates X-ray-
induced apoptosis. We ﬁrst investigated whether S662 in
PER2 is crucial for its function as a tumor suppressor by
analyzing the apoptotic response. To avoid potential
interference from the wild-type Per2 gene, we crossed both
PER2
S662G and PER2
S662D (amino acid 662 changed from
serine to aspartate) bacterial artiﬁcial chromosome (BAC)
transgenic mice to a Per2
 /  background.
15,17 The resultant
compound mice, aged 8–10 weeks, were treated with 6-Gy
X-ray irradiation at Zeitgeber Time (ZT) 0 and ZT 9. The
percentage of apoptotic spleen cells was reduced
signiﬁcantly (approximately two fold) in Per2
 /  spleens
compared with those of wild-type littermates at ZT 0 and ZT
9, as shown by ﬂow cytometry (Figures 1a and b).
Interestingly, the cells from PER2
S662G:Per2
 /  mice
displayed markedly attenuated levels of apoptosis that
were similar to those of Per2
 /  mice, and
PER2
S662D:Per2
 /  mice were even more resistant to
X-ray-induced apoptosis than Per2 knockout (KO) mice
(Figure 1b).
Generation of PER2 dose-dependent BAC transgenic
mice. As there is a higher level of PER2 in PER2
S662D mice
compared with wild-type littermates,
15 it is plausible that
PER2 may affect apoptosis through multiple mechanisms. To
determine whether increased expression of PER2 compared
with wild-type levels is also responsible for the observed
resistance to apoptosis, we generated PER2 dose-
dependent BAC transgenic mice (Figure 2a). These
transgenic mice were designed to express cis-acting
genomic regulatory elements in a manner that faithfully
recapitulates endogenous PER2 expression. We
characterized these mice based on their copy number by
Southern blot (Figure 2b) and quantitative-PCR (Q-PCR)
(Figure 2c), and then we selected three transgenic lines as
low (1–2 copies) (L), middle (2–3 copies) (M) and high copy
(4–5 copies) (H). mRNA levels are much higher in the H line
than in the PER2
S662D2H in including liver (Figure 2d), spleen
(Figure 2e) and mouse embryonic ﬁbroblasts (MEFs)
(Figure 2f), and PER2 protein in H line is more abundant
than those from the PER2
S662D mice (Figure 2g). These mice
have a circadian period that lengthens as the copy number of
Per2 increases (Figure 2h). Mice with four to ﬁve copies of
the PER2 transgene showed an extreme elongation of the
circadian period to 25h, which is longer than that of the mice
with the PER2
S662D mutation (24h).
15 The PER2 dose
dependence of period length suggests that PER2 has a
critical role in circadian clock, which is also seen in
dorosphila.
18,19 PER2
S662D may elongate the circadian
period through the increased PER2 protein level. We
noticed that apoptosis rates also decreased in the high-
copy mice (28%±0.9), but this decrease is less than
that in the PER2
S662G:Per2
 /  mutant (16.5%±0.3),
PER2
S662D:Per2
 /  mutant (9.9%±0.05) and Per2
 /  mice
(15.08%±0.2) (Po0.001) (Figures 3a and b). This suggests
that PER2 homeostasis has a role in maintaining a proper
apoptosis response. Furthermore, we crossed L-line mice to
the Per2
 /  background because all results are on a Per2
 / 
background. The cells from L-line mice displayed com-
parable levels of apoptosis to those from L line on a Per2
 / 
background (35.1±0.1 versus 35.2±0.5), to exclude a
remote possibility that Per2
–/– acts as a dominant negative
role. These genetic observations suggest that both the
mutational status of PER2
S662 and the levels of PER2 protein
may affect the apoptotic response to X-rays.
Mutation of S662 promotes oncogenic E1A–RAS-
induced transformation in MEFs. A previous study has
shown that primary embryo ﬁbroblasts can be immortalized
by the expression of at least two oncogenes; for example,
E1A, myc and ras.
20 This technique has been used to
evaluate whether inactivation or deletion of a tumor
suppressor gene can hasten the activation of oncogenes
and promote oncogenic transformation.
21 To determine
whether the PER2
S662 mutation results in a transformation-
permissive phenotype in vitro, PER2
S662G, PER2
S662D, wild-
type and Per2
 /  MEFs were infected with a retroviral vector
that co-expressed the oncogenes E1a and Ras. The ability of
E1a and Ras to induce cellular transformation was far greater
in PER2
S662G mice than in wild-type MEFs, while the level of
transformation was comparable to that of Per2 KO MEFs
(Figures 4a and b). Furthermore, consistent with the
phenotype shown for X-ray-induced apoptosis, PER2
S662D
MEFs formed more colonies than PER2
S662G and Per2
 / 
MEFs (Figures 4a and b). Finally, we assessed whether
overexpression of wild-type PER2 could trigger cellular
transformation. As expected, the MEFs with a high-copy
number of Per2 from H line grew more colonies than
those with a low-copy number of Per2 or wild-type MEFs,
but they grew fewer colonies than PER2
S662D mutant MEFs
(Figures 4c and d). The numbers for E1a- and Ras-induced
transformation foci are 310±107 for PER2
S662D, 205±52 for
H line, 158±25 for Per2
 / , 150±36 for PER2
S662G,9 6 ±24
for L line, 74±35 for wild type and 8±5 for no-transfection
control. These mice are on a wild-type background because
of technical difﬁculty getting all embryos from seven
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 /  background at one time. These
ﬁndings are consistent with the apoptotic responses
observed after X-ray exposure. Furthermore, similar
transformation rates between PER2
S662G on wild-type
background and Per2
 / MEFs suggest that PER2
S662G is
not just a loss of function mutation but has a dominant role.
Altogether, these results illustrate the importance of the S662
site and of maintaining an appropriate level of PER2 to
mediate the cellular response to environmental mutagens.
Mutations in PER2
S662 accelerate tumorigenesis in
p53
R172H/þ background mice. The inﬂuence of PER2
S662
mutations on both X-ray-induced apoptosis and in vitro
transformation led us to assess the relevance of the
PER2
S662 mutation with regard to tumorigenesis in vivo.I t
has been noted that a mutation in one or more core clock
genes is not sufﬁcient to elicit increased tumor incidence in
the absence of a cancer-sensitized genetic background.
22
As the PER2
S662 mutation is found in a human circadian
variant, we mated PER2
S662 mutant mice with p53
R172H
knock-in mice. These knock-in mice have a mutation
that corresponds to the p53
R175H hot spot in human
cancers.
16 Through breeding, we established cohorts of
p53
R172H/þ (n¼54), PER2
S662G2H:p53
R172H/þ (n¼41),
PER2
S662D2H:p53
R172H/þ (n¼31) and Clock
D19/þ:p53
R172H/þ
(n¼29) compound mutantmice. These miceall hadthe same
genetic background of C57BL/6. We monitored these mice for
tumor development and survival for up to 700 days. As shown
in Figure 5a, Kaplan–Meier overall survival curves of these
compound mutant mice showed slight but signiﬁcant differ-
ences (log-rank test, P¼0.049). A closer inspection of the
data revealed that the survival of female p53
R172H/þ and
Clock
D19/þ:p53
R172H/þ mice was decreased markedly com-
paredwiththatofmalemice(SupplementaryFiguresS1Aand
B). But the survival of PER2
S662G2H:p53
R172H/þ and
PER2
S662D2H:p53
R172H/þ mice did not show any gender-
based differences (Supplementary Figures S1C and 1D).
Thus, to further dissociate the effects of the PER2
S662
mutation on tumor development, we assessed male and
female survival curves separately. The survival curve for
males was signiﬁcantly affected by circadian gene mutations
(Figure 5b, log-rank test, Po0.001). The median life spans
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Figure 1 The PER2
S662 mutation leads to decreased levels of apoptosis. (a) Wild-type, Per2
 / , PER2
S662G:Per2
 /  and PER2
S662D:Per2
 /  mice were irradiated with
6GyX-raysatZT0(0800hours)andZT9(1700hours).Spleencellswereisolated6hafterirradiation,stainedwithpropidiumiodide(PI)andanalyzedbyﬂowcytometry.One
representativeexperimentisshown.Ap,apoptoticpercentage.(b)Percentagesofapoptoticcellsmeasuredbyﬂowcytometryareshowninthehistograms.Experimentswere
repeated at least three times with consistent results and at least two mice were used per group for each time (N¼3 for each genotype; ***Po0.001; one-way ANOVA
followed by Dunnett’s test)
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Cell Death and Differentiationwere also reduced for male PER2
S662D2H:p53
R172H/þ (15.0
months) and PER2
S662G2H:p53
R172H/þ (16.6 months) mice
compared with those of male p53
R172H/þ (17.9 months) and
Clock
D19/þ:p53
R172H/þ (19.8 months) mice (Figure 5b). As
tumors in p53
R172H/þ mice arise after a similar length
of latency, these differences in the survival curves and
median life spans reﬂected changes that contributed to
tumorigenesis.
This raises the question of why female and male on a
p53
R172H/þ background have different survival rates, and
why we did not observe a difference between
PER2
S6622H:p53
R172H/þ2 and p53
R172H/þ female mice, in
contrast to the male mice. Of note, we did not obtain any
p53
R172H/R172H female homozygous mice from 75 pups
(Supplementary Table 1), and we found that they all died by
13.5 days as a result of fatal embryonic exencephaly
(Figure 6). These ﬁndings are consistent with a previous
reportingthatlackofthetumorsuppressorproteinp53causes
a female-speciﬁc disruption of neural tube closure associated
withembryonicorneonataldeath.
23Thissuggeststhatfemale
p53
R172H/þ mice may have a penetrant phenotype that could
have masked the effects of PER2
S662 mutations on female
tumorigenesis. These data demonstrate collectively that the
PER2
S662 mutation has an impact on tumor development in
the p53
R172H/þ mutant background.
Circadian cycle length is not tightly associated with
tumorigenesis. Then, we tested whether the accelerated
tumorigenesis caused by PER2
S662 mutation was related to
the alteration in circadian period. As shown in Supplementary
Figures 2A and B, the p53
R172H/þ mutation did not
affect the circadian period or the expression of core
clock genes. Furthermore, in the PER2
S662G2H:
p53
R172H/þ, PER2
S662D2H:p53
R172H/þ and Clock
D19/
þ:p53
R172H/þ mice, circadian period was not closely
related to tumor development (Figure 5a and
Supplementary Figure S2C).
The most common tumor types observed in mice of the
above genotypes are lymphomas and sarcomas, consistent
with the reported tumor ratio of p53
R172H/þ mice (Supple-
mentary Figure S3).
16 It is noteworthy that the incidence of
primary hepatic malignancy and metastatic tumors was
increased in PER2
S662G2H:p53
R172H/þ (27.3%) and
PER2
S662D2H:p53
R172H/þ mice (19.4%) compared with that
in p53
R172H/þ mice (8.7%), although it did not reach statistical
signiﬁcance (P¼0.17) (Table 1). We observed that circadian
cycle length was also not associated with certain types of
tumors (Table 1). These results support the notion that
mutation of PER2 at S662 promotes tumorigenesis,
independent of the acceleration or deceleration of the
circadian clock.
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Figure 2 Generation and characterization of PER2 BAC transgenic mice. (a) Generation of different copy BAC transgenic mice. (b) Transgene copy number was
estimatedbySouthernblotbycomparingwithcopystandards.Experimentswererepeatedtwotimeswithconsistentresultsandonemousewasusedperline.(c)Therelative
transgene copy number was further estimated by q-PCR. (d–f) The mRNA expression level was assessed by qRT-PCR in liver tissues (d), spleen tissues (e) and non-
synchronized MEFs (f) of different BAC transgenic mice as indicated genotypes. Experiments were repeated independently at least three times with consistent results and at
least two replicates were used per time point. ‘-’ denotes the band of PER2 and ‘*’ denotes a unspeciﬁc band. (g) PER2 protein levels in spleen tissues of H line and
PER2
S662D. Experiments were repeated three times with consistent results, and one mouse for each time point was used for western blot. (h) Voluntary locomotor activities
wererecordedaswheel-runningactivity.BACtransgenicmiceweresubjectedﬁrsttoLD(lightanddarkcycle)andthenreleasedintoDD(darkanddarkcycle).Representative
actograms from low- (23.64±0.11, n¼6), middle- (24.34±0.18, n¼7) and high-copy BAC transgenic mice (25.07±0.17, n¼9). Alternating white and dark bars indicate
the LD cycles during entrainment before release in DD
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Cell Death and DifferentiationPER2
S662 affects changes in the relative phases of clock-
controlled cell cycle gene. To understand the mechanism
underlying tumorigenesis, the clock-related cell cycle genes
p21, c-Myc, Cyclin D1 and p27 were assayed in Per2
allele mutant MEFs. Unexpectedly, in several independent
experiments, the expression levels of these circadian-related
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Figure 3 High-dose PER2 results in resistance to apoptosis induced by X-rays. (a) Low-, middle- and high-copy PER2 mice were irradiated with 6Gy X-rays at ZT 9.
Spleen cells were isolated 6h after irradiation and the DNA content was analyzed by ﬂow cytometry. One representative experiment is shown. (b) Percentages of apoptotic
cells detected by ﬂow cytometry from low-, middle- and high-copy BAC transgenic spleens (***Po0.001; one-way ANOVA followed by Dunnett’s test)
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Figure 4 Dysregulation of PER2 increases formation of oncogenic E1A–RAS-mediated foci in MEFs. (a) and (c) Passage 0 MEFs with the indicated genotypes were
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Cell Death and Differentiationcell cycle regulators are not signiﬁcantly different in Per2
allele mutant MEFs compared with the wild-type (Figure 7
and Supplementary Figure S4). We noticed that p21
transcripts show peak levels when Cyclin D attains trough
levels in the wild-type MEFs. However, the relative phases of
p21 and Cyclin D appear to be highly similar in these Per2
allele mutant MEFs in contrast to the wild-type MEFs. It is
important to note that p21 transcript phases are delayed in
Per2 allele mutant MEFs, which may bring changes in the
relative phases between p21 and Cyclin D (Figure 7).
For the p21 gene, it has been described previously that its
regulatory region contains a RORE binding site and is
regulated by the antagonistic activities of the orphan nuclear
receptors NR1D1/2 and NR1F1.
24 The question then arises
as to whether NR1D1 mediates the p21 phase shifting.
Therefore, we examined the transcription proﬁles of Nr1d1 to
compare the results obtained from p21 and Cyclin D.W e
found the accumulation of Nr1d11 cycles with an antiphase to
that of p21 transcription in the wild-type MEFs, indicating that
NR1D1 inhibits the transcription of p21 expression as
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Table 1 Tumor spectrum analysis of PER2
S662G2H:p53
R172H/+, PER2
S662D2H:p53
R172H/+and p53
R172H/+ mice
Tumor types p53
R172H PER2
S662G2H:p53
R172H PER2
S662D2H:p53
R172H
Lymphoma 13/46 (28.2%) 6/33 (18.2%) 7/31 (22.6%)
Osteosarcoma 14/46 (36.1%) 10/33 (30.3%) 9/31 (29.0%)
Fibrosarcoma 7/46 (15.2%) 3/33 (9.1%) 5/31 (16.1%)
Liver tumors 4/46 (8.7%) 9/33 (27.3%) 6/31 (19.4%)
Unknown 2/46 (4.3%) 2/33 (6.1%) 4/31 (12.9%)
Multiple tumors 4/46 (8.7%) 2/33 (6.1%) 4/31 (12.9%)
Metastasis 8/46 (17.4%) 5/33 (15.2%) 4/31 (12.9%)
PER2
S662G, cell cycle and tumorigenesis
XG uet al
402
Cell Death and Differentiationdescribed previously.
24 While in these mutant MEFs, p21
expression proﬁles are uncoupled at least in part from Nr1d1
expression (Figure 7), thereby offering the possibility that
NR1D1 needs wild-type PER2 to regulate the phase of p21
expression. In addition, as shown in Figure 7, the cycles of
Nr1d1 transcriptsrespond tointrinsic circadian period in these
mutant MEFs, while the periods of p21 and Cyclin D seem to
be ﬁxed 24h in these mutant MEFs no matter whether they
own short or long circadian period. Moreover, the phases of
p21 transcripts delay to the same extend in Per2 allele mutant
MEFs, suggesting that the ability of the circadian control of
p21 expression has been abolished when PER2 is mutated,
which is mediated mainly through NR1D1. This assumption is
supported by a recent study by Isabelle Schmutz et al.
5
demonstrating that PER2 coordinates circadian output by
interacting with NR1D1.
The p21 protein inhibits the activity of cyclin–CDK2 or –CDK4
complexes,andfunctionsasaregulatorof cellcycleprogression
at G1.
25 Although the p21 expression levels in these PER2
mutant MEFs remains comparable to that of wild-type MEFs,
the peak of p21 is locked to the abnormal region that overlaps
with the peak of the cyclin D phase. It is conceivable that the
p21/cyclinDintervalvariationsmaytriggercellcycleprogression.
Discussion
The physiological relevance of the PER2
S662 mutation to
human cancer. In this study, we provided evidence that the
human PER2
S662G mutation, which causes the FASPS
circadian variant, is also responsible for increased cancer
risk. To our knowledge, this represents the ﬁrst instance of
experimental evidence that links a human circadian mutation
to cancer risk. Although the cancer incidence data in FASPS
individuals are unavailable owing to scarcity of sampling (one
family), a missense mutation in the evolutionarily conserved
residue of hPER2 (L823V) has been identiﬁed in some human
breast cancer samples
26 and altered PER2 expression is
common in human breast malignancies.
27,28 By comparing the
X-ray-induced apoptosis level and transformation rate among
Per2
 / , PER2
S662G, PER2
S662D and PER2 dose-dependent
BAC transgenic mice, we suggested that PER2
S662G is a
dominant negative mutation and PER2
S662D gains extra
function to prevent apoptosis and increase transformation
rate. Interestingly, the functional alternations of PER2
S662G and
PER2
S662D displayed in the aspect of cell cycle are different
from that in circadian clock, because PER2
S662G mice show
shorter circadian period length than Per2
 /  mice and
PER2
S662D might elongate the circadian period through
increasing PER2 protein level. Furthermore, our data that
overexpressing and knockout PER2 both trigger more
transformation foci and affect normal apoptosis function
suggest that maintaining an optimal level of PER2 is critical
to reduce the risk of tumorigenesis. Our functional studies of
human variants of PER2, together with unbiased analyses in
human cancer by other groups, indicate the importance of
PER2 in human tumorigenesis. But the hypothesis that the
FASPS mutation increases cancer risk in humans remains to
be tested in future.
Impaired gene expression or impaired circadian
rhythms? Previous work has demonstrated that the
PER2
S662G and PER2
S662D mutations give rise to
completely contrary circadian phenotypes in terms of
circadian period, phase and amplitude;
15 thus, we predicted
Nr1d1
p21
CyclinD
PER2
S662G PER2
S662D Per2
-/- H line Wild-type
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Figure 7 The relative phases of cell cycle genes are shifted by PER2 mutations. Wild-type and different PER2 mutant MEFs were synchronized by a dexamethasone
treatment, and RNA was extracted at 3h intervals stating 10h after the shock. p21, Cyclin D1 and Nr1d1 expression analysis were done by q-PCR. Experiments were
repeatedindependentlyat leastthreetimeswith consistent results.Plottedvaluesare themeanvalues±S.D.Cosinoranalysiswasperformedon mRNAproﬁlesusingSPSS
17.0. The amplitude and acrophase obtained from cosinor analysis were further analyzed by Students t-test. The null hypothesis was rejected at Po0.05
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S662G and PER2
S662D mutant mice should have
contrary cancer risks if impaired rhythm is the culprit.
However, the enhanced cancer risk in both
PER2
S662G2H:p53
R172H/þ and PER2
S662D2H:p53
R172H/þ
mice strongly suggested that the impaired PER2 gene, not
the impaired circadian rhythm, is responsible for the
increased cancer risk in these mice. This observation is
further supported by survival data from the
PER2
S662D2H:p53
R172H/þ and Clock
D19/þ:p53
R172H/þ mice,
both of which exhibited lengthened circadian periods, but
showed highly contrary cancer risks. Interestingly, the
‘impaired gene’ theory is consistent with the observation
from cancer risks in Cry1
 / :Cry2
 /  mice
22,29 and Clock
D19
mutant mice.
30 In addition, we wish to point out that our
experiments share an important similarity with the above-
mentioned investigations; all of these experimental systems
retain the circadian mutant mice on normal light/dark cycles
and subject these mice to entrainment from external time
cues. Accordingly, the ‘impaired gene’ theory may only apply
to circadian mutant mice kept in normal light/dark cycles.
Circadian disruption is not as intense or detrimental in normal
cycles as the disruption experienced by shift workers. In this
regard, an important future direction may focus on both the
respective contribution and the composite consequence of
disrupted circadian genes, as well as disrupted circadian
rhythm to cancer risk in persistent phase-shifted schedules.
The cell cycle, circadian clock and relative
phase. Recent studies have shown that the circadian clock
is coupled to the cell cycle processes through clock-
controlled genes, which may contain E-box or ROR
elements in their promoters. Somewhat surprisingly,
although we found that deregulation of PER2 has a strong
effect on the induced transformation of MEFs and
tumorigenesis; the gene expression changes in these
clock-controlled genes are less profound in Per2 allele
mutant MEFs. This leads us to think about their phase
implication. Although the Nr1d1 transcripts displayed obvious
phase shift and period length changes in these mutant
MEFS, p21 transcripts displayed ﬁxed 24-h-period oscillation
with phase delay to the same extent, leading to a similar
phase to that of Cyclin D. It indicates that in the wide-type
MEFs, the opposite phases of p21 and Cyclin D are a result
of coordination between circadian clock and cell cycle, with
circadian clock adjusting transcription phase of p21 and the
main driver of cell cycle. With the interaction of PER2,
NR1D1 may be a critical circadian factor in exerting the
phase adjusting function. At present, the physiological
signiﬁcance of the altered phases of these genes is
unclear, and the phase shifting cannot explain all the
phenotypes that are seen in these mutant mice. It is likely
that modiﬁer relative phases between the cycle genes
inﬂuence features such as the number of transformation
foci and the development of the tumor-associated ﬁbroblasts.
One of the possibilities comes from interfering with phase
locking. Oscillation-based synchrony is the most energy-
efﬁcient physical mechanism for temporal coordination. It
occurs in many biological systems, including two oscillators
of cell division and the circadian phase
31 or within a cell cycle
oscillator through multiple regulatory interactions.
32 It is
conceivable that, if phase-coupled p21 appears at a later
phase of the inhibitory cycle while Cyclin D remains
unchanged, the corresponding inhibition of the CDK
complex becomes weak. In other words, if the threshold is
reached, CDK activation can initialize unexpected cell cycle
progression. It would be interesting, therefore, to investigate
the extent to which relative phase changes might affect cell
cycle progression, transformation and tumorigenesis.
Materials and Methods
Animals. Mice were observed daily and killed when they showed signs of
morbidity or tumor growth in accordance to the Guidelines for Human Endpoints for
Animals Used in Biomedical Research. Mice were housed in an Assessment And
Accreditation Of Laboratory Animal Care credited SPF animal facility.
PER2
S662G5H:p53
R175H/þ, PER2
S662D5H: p53
R175H/þ, Clock
D19/þ:p53
R175H/þ
mice and their littermates were derived from PER2
S662 mutants and Clock
D19
mutants
33 by crossing with p53
R175H/þ mice. All mutant animals have been
backcrossed for more than 10 generations onto a C57BL/6 inbred background.
Low-, middle- and high-copy PER2 BAC transgenic mice were generated, as
described previously.
15 Locomotor activity and activity pattern analyses were
performed, as described previously.
34
X-rayand ﬂowcytometer. Micewere radiatedat theindicatedZT timeswith
a single dose of 6Gy (100cGy/min) with a XHA600C Medical Electron Linear Accelerator
(Shinva Medical Instrument Co., Ltd, Zibo, Shandong, China). Splenic lymphocytes were
isolated at 6h after irradiation, and red cells were removed using Gey’s solution. For ﬂow
cytometer analyses, splenic lymphocytes were centrifuged at 1000r.p.m., and the
supernatants were thoroughly removed by aspiration and ﬁxed in 70% ethanol. After
incubation with 40mg/ml propidium iodide and 100mg/ml RNase at 371C for 30min, the
samples were analyzed with a Becton Dickinson FACScan ﬂow cytometer using
CellQuest software (Becton Dickinson, Auckland, New Zealand).
Retroviral transfection and focus formation assays. The Plate-E
virus packaging cells were transfected with the retroviral vector pMXs carrying the
cDNA encoding E1A and Ras or pMXs with GFP as the control using PEI as the
transfection reagent.
35 Culture media collected 2 days after transfection were used
for infection. MEFs were isolated from 13.5-day embryos as described. P1 MEFs
were incubated with fresh virus for 6h. One day after infection, the medium was
replaced with fresh DMEM supplemented with 5% fetal bovine serum and
purimycin, and the cells were selected after another 48h. The infection efﬁciency
was 495%, as estimated by a control experiment. After selection, the cells were
plated at 1 10
6cells/6cm
2 for 14 days. The medium was changed every 2 days.
Conﬂuent monolayer cultures with foci were rinsed with phosphate buffered saline
(PBS), ﬁxed in 10% formalin and stained with 0.1% crystal violet for 20min;
subsequently, the colonies were scored.
Tumorigenesis. Cohorts of mice were monitored carefully for signs of
morbidity or obvious tumor burden. Mice with visible neoplasms around 2cm in
diameter were killed and necropsied. Mice with ill health but no visible neoplasms
were monitored carefully for signs of morbidity. Moribund mice or mice that died
without signs of morbidity were also necropsied. In most cases, tumor-burdened
mice could be identiﬁed through necropsy and all tissues with suspected gross
lesions or neoplasms were further examined by histopathological examination.
Samples were ﬁxed in neutral buffered formalin. Tissues with osseous structure
were decalciﬁed with 10% hydrochloric acid. Parafﬁn sections were prepared and
stainedwithhematoxylinandeosinfollowingstandardprocedures.Tumorspectrum
analysis was performed blindly with the assistance of a clinical pathologist.
Q-PCR and reverse transcription-PCR (RT-PCR). Primers are listed
in Supplementary Table 2. All procedures were carried out as previously
described.
34
Western blotting. Tissue proteins were prepared as described previously
using a nuclear extraction kit at the indicated circadian time (Active Motif, Carlsbad,
CA, USA). Rabbit anticyclin E and antiPPARa (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) were utilized for western blotting according to the manufacturer’s
suggested protocol.
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Cell Death and DifferentiationStatistical analysis. Groups of data are presented as mean±S.D. One-way
analysisofvariance(ANOVA)followedbyDunnett’stestorStudentst-testwasused
to determine the statistical signiﬁcance of difference in measured parameters.
Difference was considered signiﬁcant at Po0.05. Cosinor analysis was performed
on mRNA proﬁles using SPSS 17.0. The amplitude and acrophase obtained from
cosinor analysis were further analyzed by Students t-test. The null hypothesis was
rejected at Po0.05.
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